Loading…
Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer
Background Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC). Methods This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally...
Saved in:
| Published in: | Journal of surgical oncology 2024-09, Vol.130 (4), p.681-690 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c2435-bc569ce859b53171ba5e2060b02b6ba42934f6b7629f0b095d06308de634d10a3 |
| container_end_page | 690 |
| container_issue | 4 |
| container_start_page | 681 |
| container_title | Journal of surgical oncology |
| container_volume | 130 |
| creator | Salgado, Marcelo Ramos Tejo Sobral, Denise Viana Martins, Mario R. Salgado, Eduardo Forte M. T. Salgado, Amanda Forte M. T. Silva, Kamylla Ramos da Soares, Fernando Augusto Torres, Leuridan C. |
| description | Background
Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC).
Methods
This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre‐NAC) and after NAC (Post‐NAC).
Results
Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p |
| doi_str_mv | 10.1002/jso.27725 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3065985534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3065985534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2435-bc569ce859b53171ba5e2060b02b6ba42934f6b7629f0b095d06308de634d10a3</originalsourceid><addsrcrecordid>eNp10ctu1DAUBmALUdGhsOgLIEtsijRpfU-8HE1vVCMVqWVt2clJm5ETD3bSaXc8As_Ik-AyhQUSK0vHn38d-UfokJJjSgg7WadwzMqSyVdoRolWhSa6eo1m-Y4VotRkH71NaU0I0VqJN2ifV5WQjPIZ8mePmwgpdWHAocXLU1bN8fniZo6_nNI5tkODl7erhcB98FBPHhLuBjzeA3Y-hOb5zTb0MOBtN97jMXYbDz-__xjgzo7dQ1YRbBpxbYca4ju011qf4P3LeYC-np_dLi-L1fXF5-ViVdRMcFm4WipdQyW1k5yW1FkJjCjiCHPKWcE0F61ypWK6zUMtG6I4qRpQXDSUWH6Ajna5mxi-TZBG03epBu_tAGFKhhMldSUlF5l-_IeuwxSHvJ3hlFMlJFc6q087VceQUoTWbGLX2_hkKDHPFZhcgfldQbYfXhIn10PzV_758wxOdmDbeXj6f5K5urneRf4CZzqNaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3131645369</pqid></control><display><type>article</type><title>Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer</title><source>Wiley</source><creator>Salgado, Marcelo Ramos Tejo ; Sobral, Denise Viana ; Martins, Mario R. ; Salgado, Eduardo Forte M. T. ; Salgado, Amanda Forte M. T. ; Silva, Kamylla Ramos da ; Soares, Fernando Augusto ; Torres, Leuridan C.</creator><creatorcontrib>Salgado, Marcelo Ramos Tejo ; Sobral, Denise Viana ; Martins, Mario R. ; Salgado, Eduardo Forte M. T. ; Salgado, Amanda Forte M. T. ; Silva, Kamylla Ramos da ; Soares, Fernando Augusto ; Torres, Leuridan C.</creatorcontrib><description>Background
Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC).
Methods
This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre‐NAC) and after NAC (Post‐NAC).
Results
Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p < 0.05). Patients with pathological complete response (pCR) had low FAS+ T cells, FAS+CD4+ T cells, and PD1+CD8+ T cells compared to the non‐pCR (p < 0.05). Significant differences were observed in the levels of CD28+ T cells, FAS+ T and PD1+ T, CD4+ T, CD28+CD4+ T, FAS+CD4+ T, PD1+CD4+ T, CD8+ T, and PD1+CD8+ T cells between Pre‐NAC and Post‐NAC groups (p < 0.05).
Conclusion
Alterations in the circulating FAS+CD4+ T and PD1+CD8+ T cell levels Pre‐NAC are associated with pCR, suggesting potential predictive biomarkers of NAC response in TNBC. The largest changes in the cellular immune response profile Post‐NAC showed that chemotherapy treatment can modulate the immune response and that it is associated with prognosis in TNBC.</description><identifier>ISSN: 0022-4790</identifier><identifier>ISSN: 1096-9098</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.27725</identifier><identifier>PMID: 38845213</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - blood ; Breast cancer ; Case-Control Studies ; CD28 Antigens - blood ; Chemotherapy ; CTLA-4 Antigen - blood ; fas Receptor - blood ; Female ; Follow-Up Studies ; Humans ; immune system ; Longitudinal Studies ; Lymphocytes ; Middle Aged ; Neoadjuvant Therapy ; Prognosis ; Programmed Cell Death 1 Receptor ; T lymphocytes ; triple negative breast neoplasms ; Triple Negative Breast Neoplasms - blood ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - pathology</subject><ispartof>Journal of surgical oncology, 2024-09, Vol.130 (4), p.681-690</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2435-bc569ce859b53171ba5e2060b02b6ba42934f6b7629f0b095d06308de634d10a3</cites><orcidid>0000-0001-8705-8210</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38845213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salgado, Marcelo Ramos Tejo</creatorcontrib><creatorcontrib>Sobral, Denise Viana</creatorcontrib><creatorcontrib>Martins, Mario R.</creatorcontrib><creatorcontrib>Salgado, Eduardo Forte M. T.</creatorcontrib><creatorcontrib>Salgado, Amanda Forte M. T.</creatorcontrib><creatorcontrib>Silva, Kamylla Ramos da</creatorcontrib><creatorcontrib>Soares, Fernando Augusto</creatorcontrib><creatorcontrib>Torres, Leuridan C.</creatorcontrib><title>Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer</title><title>Journal of surgical oncology</title><addtitle>J Surg Oncol</addtitle><description>Background
Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC).
Methods
This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre‐NAC) and after NAC (Post‐NAC).
Results
Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p < 0.05). Patients with pathological complete response (pCR) had low FAS+ T cells, FAS+CD4+ T cells, and PD1+CD8+ T cells compared to the non‐pCR (p < 0.05). Significant differences were observed in the levels of CD28+ T cells, FAS+ T and PD1+ T, CD4+ T, CD28+CD4+ T, FAS+CD4+ T, PD1+CD4+ T, CD8+ T, and PD1+CD8+ T cells between Pre‐NAC and Post‐NAC groups (p < 0.05).
Conclusion
Alterations in the circulating FAS+CD4+ T and PD1+CD8+ T cell levels Pre‐NAC are associated with pCR, suggesting potential predictive biomarkers of NAC response in TNBC. The largest changes in the cellular immune response profile Post‐NAC showed that chemotherapy treatment can modulate the immune response and that it is associated with prognosis in TNBC.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - blood</subject><subject>Breast cancer</subject><subject>Case-Control Studies</subject><subject>CD28 Antigens - blood</subject><subject>Chemotherapy</subject><subject>CTLA-4 Antigen - blood</subject><subject>fas Receptor - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>immune system</subject><subject>Longitudinal Studies</subject><subject>Lymphocytes</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Prognosis</subject><subject>Programmed Cell Death 1 Receptor</subject><subject>T lymphocytes</subject><subject>triple negative breast neoplasms</subject><subject>Triple Negative Breast Neoplasms - blood</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><issn>0022-4790</issn><issn>1096-9098</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10ctu1DAUBmALUdGhsOgLIEtsijRpfU-8HE1vVCMVqWVt2clJm5ETD3bSaXc8As_Ik-AyhQUSK0vHn38d-UfokJJjSgg7WadwzMqSyVdoRolWhSa6eo1m-Y4VotRkH71NaU0I0VqJN2ifV5WQjPIZ8mePmwgpdWHAocXLU1bN8fniZo6_nNI5tkODl7erhcB98FBPHhLuBjzeA3Y-hOb5zTb0MOBtN97jMXYbDz-__xjgzo7dQ1YRbBpxbYca4ju011qf4P3LeYC-np_dLi-L1fXF5-ViVdRMcFm4WipdQyW1k5yW1FkJjCjiCHPKWcE0F61ypWK6zUMtG6I4qRpQXDSUWH6Ajna5mxi-TZBG03epBu_tAGFKhhMldSUlF5l-_IeuwxSHvJ3hlFMlJFc6q087VceQUoTWbGLX2_hkKDHPFZhcgfldQbYfXhIn10PzV_758wxOdmDbeXj6f5K5urneRf4CZzqNaw</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Salgado, Marcelo Ramos Tejo</creator><creator>Sobral, Denise Viana</creator><creator>Martins, Mario R.</creator><creator>Salgado, Eduardo Forte M. T.</creator><creator>Salgado, Amanda Forte M. T.</creator><creator>Silva, Kamylla Ramos da</creator><creator>Soares, Fernando Augusto</creator><creator>Torres, Leuridan C.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8705-8210</orcidid></search><sort><creationdate>20240901</creationdate><title>Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer</title><author>Salgado, Marcelo Ramos Tejo ; Sobral, Denise Viana ; Martins, Mario R. ; Salgado, Eduardo Forte M. T. ; Salgado, Amanda Forte M. T. ; Silva, Kamylla Ramos da ; Soares, Fernando Augusto ; Torres, Leuridan C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2435-bc569ce859b53171ba5e2060b02b6ba42934f6b7629f0b095d06308de634d10a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - blood</topic><topic>Breast cancer</topic><topic>Case-Control Studies</topic><topic>CD28 Antigens - blood</topic><topic>Chemotherapy</topic><topic>CTLA-4 Antigen - blood</topic><topic>fas Receptor - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>immune system</topic><topic>Longitudinal Studies</topic><topic>Lymphocytes</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Prognosis</topic><topic>Programmed Cell Death 1 Receptor</topic><topic>T lymphocytes</topic><topic>triple negative breast neoplasms</topic><topic>Triple Negative Breast Neoplasms - blood</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salgado, Marcelo Ramos Tejo</creatorcontrib><creatorcontrib>Sobral, Denise Viana</creatorcontrib><creatorcontrib>Martins, Mario R.</creatorcontrib><creatorcontrib>Salgado, Eduardo Forte M. T.</creatorcontrib><creatorcontrib>Salgado, Amanda Forte M. T.</creatorcontrib><creatorcontrib>Silva, Kamylla Ramos da</creatorcontrib><creatorcontrib>Soares, Fernando Augusto</creatorcontrib><creatorcontrib>Torres, Leuridan C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salgado, Marcelo Ramos Tejo</au><au>Sobral, Denise Viana</au><au>Martins, Mario R.</au><au>Salgado, Eduardo Forte M. T.</au><au>Salgado, Amanda Forte M. T.</au><au>Silva, Kamylla Ramos da</au><au>Soares, Fernando Augusto</au><au>Torres, Leuridan C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J Surg Oncol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>130</volume><issue>4</issue><spage>681</spage><epage>690</epage><pages>681-690</pages><issn>0022-4790</issn><issn>1096-9098</issn><eissn>1096-9098</eissn><abstract>Background
Locally advanced triple‐negative breast cancer (TNBC) represents a public health problem in Brazil. Its standard treatment consists of neoadjuvant chemotherapy (NAC).
Methods
This was a longitudinal study with follow‐up performed between the years 2015 and 2017. Thirty women with locally advanced TNBC submitted to NAC, and 30 healthy were included. Peripheral blood samples were collected before NAC (Pre‐NAC) and after NAC (Post‐NAC).
Results
Patients with TNBC had elevated levels of CD28+ T, FAS+ T, CTLA4+ T, PD1+ T, CD28+CD4+ T, PD1+CD4+ T and CD8+ T and PD1+ CD8+ T cells compared to controls (p < 0.05). Patients with pathological complete response (pCR) had low FAS+ T cells, FAS+CD4+ T cells, and PD1+CD8+ T cells compared to the non‐pCR (p < 0.05). Significant differences were observed in the levels of CD28+ T cells, FAS+ T and PD1+ T, CD4+ T, CD28+CD4+ T, FAS+CD4+ T, PD1+CD4+ T, CD8+ T, and PD1+CD8+ T cells between Pre‐NAC and Post‐NAC groups (p < 0.05).
Conclusion
Alterations in the circulating FAS+CD4+ T and PD1+CD8+ T cell levels Pre‐NAC are associated with pCR, suggesting potential predictive biomarkers of NAC response in TNBC. The largest changes in the cellular immune response profile Post‐NAC showed that chemotherapy treatment can modulate the immune response and that it is associated with prognosis in TNBC.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38845213</pmid><doi>10.1002/jso.27725</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8705-8210</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2024-09, Vol.130 (4), p.681-690 |
| issn | 0022-4790 1096-9098 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3065985534 |
| source | Wiley |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - blood Breast cancer Case-Control Studies CD28 Antigens - blood Chemotherapy CTLA-4 Antigen - blood fas Receptor - blood Female Follow-Up Studies Humans immune system Longitudinal Studies Lymphocytes Middle Aged Neoadjuvant Therapy Prognosis Programmed Cell Death 1 Receptor T lymphocytes triple negative breast neoplasms Triple Negative Breast Neoplasms - blood Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - pathology |
| title | Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple‐negative breast cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T16%3A51%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20CD28,%20FAS,%20PD1,%20and%20CTLA4%20molecules%20in%20the%20blood%20of%20women%20with%20triple%E2%80%90negative%20breast%20cancer&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Salgado,%20Marcelo%20Ramos%20Tejo&rft.date=2024-09-01&rft.volume=130&rft.issue=4&rft.spage=681&rft.epage=690&rft.pages=681-690&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.27725&rft_dat=%3Cproquest_cross%3E3065985534%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2435-bc569ce859b53171ba5e2060b02b6ba42934f6b7629f0b095d06308de634d10a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3131645369&rft_id=info:pmid/38845213&rfr_iscdi=true |